March 4, 2019 — Since the turn of the century, the use of biomarkers in drug discovery and development has exploded at an unprecedented rate. Recent scientific and technologic breakthroughs allow biomarkers to be leveraged to address many questions about biological activity, safety, and clinical efficacy throughout the drug discovery and development process—at a fraction of the cost and with turnaround times unimaginable less than a decade ago. Chad Clark et al., of Precision for Medicine, identify how these advances are driving a paradigm shift in drug discovery and development.
The use of biomarkers in drug discovery and development has exploded at an unprecedented rate since the turn of the century. With recent scientific and technological breakthroughs—including genomics, advanced cellular and tissue profiling, and complex imaging—biomarkers can now be leveraged to address many questions about biological activity, safety, and clinical efficacy throughout the drug discovery and development process at a fraction of the cost and with turnaround times unimaginable less than a decade ago. These advances in precision medicine are driving a paradigm shift in drug discovery and development as innovators are now focusing on programs with narrow indications, shorter development times, and lower costs.
View the complete article here
Authors: Chad Clark | President, Scott Marshall, PhD| Managing Director, Cliff Culver | Senior Vice President
